Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group

Next Previous
Trial Profile

Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferasirox (Primary) ; Ciclosporin
  • Indications Iron overload
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 08 Jul 2019 Status changed from completed to discontinued.
  • 20 Apr 2017 Status changed from recruiting to completed.
  • 11 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top